CEL-SCI Corp (CVM) - Total Assets
Based on the latest financial reports, CEL-SCI Corp (CVM) holds total assets worth $22.89 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CVM total equity for net asset value and shareholders' equity analysis.
CEL-SCI Corp - Total Assets Trend (1986–2025)
This chart illustrates how CEL-SCI Corp's total assets have evolved over time, based on quarterly financial data.
CEL-SCI Corp - Asset Composition Analysis
Current Asset Composition (September 2025)
CEL-SCI Corp's total assets of $22.89 Million consist of 41.2% current assets and 58.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $10.95 Million | 38.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $303.28K | 1.1% |
| Property, Plant & Equipment | $12.90 Million | 45.8% |
| Intangible Assets | $119.86K | 0.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1986–2025)
This chart illustrates how CEL-SCI Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CEL-SCI Corp stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CEL-SCI Corp's current assets represent 41.2% of total assets in 2025, a decrease from 66.7% in 1986.
- Cash Position: Cash and equivalents constituted 38.9% of total assets in 2025, up from 33.3% in 1986.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1986.
- Asset Diversification: The largest asset category is property, plant & equipment at 45.8% of total assets.
CEL-SCI Corp Competitors by Total Assets
Key competitors of CEL-SCI Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
USA | $107.75 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.39 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Gubra A/S
CO:GUBRA
|
Denmark | Dkr1.32 Billion |
CEL-SCI Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 1.07 | 3.41 |
| Quick Ratio | 1.35 | 0.91 | 3.16 |
| Cash Ratio | 1.25 | 0.84 | 0.00 |
| Working Capital | $1.99 Million | $378.23K | $14.04 Million |
CEL-SCI Corp - Advanced Valuation Insights
This section examines the relationship between CEL-SCI Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | $28.16 Million |
| Market Capitalization | $12.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values CEL-SCI Corp's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CEL-SCI Corp's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CEL-SCI Corp (1986–2025)
The table below shows the annual total assets of CEL-SCI Corp from 1986 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $28.16 Million | +4.31% |
| 2024-09-30 | $26.99 Million | -11.58% |
| 2023-09-30 | $30.53 Million | -39.58% |
| 2022-09-30 | $50.52 Million | -33.41% |
| 2021-09-30 | $75.87 Million | +87.16% |
| 2020-09-30 | $40.54 Million | +46.75% |
| 2019-09-30 | $27.62 Million | -6.64% |
| 2018-09-30 | $29.59 Million | +29.06% |
| 2017-09-30 | $22.92 Million | +97.65% |
| 2016-09-30 | $11.60 Million | -24.92% |
| 2015-09-30 | $15.45 Million | -19.67% |
| 2014-09-30 | $19.23 Million | +77.43% |
| 2013-09-30 | $10.84 Million | -32.54% |
| 2012-09-30 | $16.07 Million | -13.73% |
| 2011-09-30 | $18.63 Million | -50.73% |
| 2010-09-30 | $37.80 Million | -17.86% |
| 2009-09-30 | $46.03 Million | +213.46% |
| 2008-09-30 | $14.68 Million | -29.17% |
| 2007-09-30 | $20.73 Million | +114.75% |
| 2006-09-30 | $9.65 Million | +212.17% |
| 2005-09-30 | $3.09 Million | -43.92% |
| 2004-09-30 | $5.51 Million | +89.14% |
| 2003-09-30 | $2.92 Million | -22.70% |
| 2002-09-30 | $3.77 Million | -16.36% |
| 2001-09-30 | $4.51 Million | -67.35% |
| 2000-09-30 | $13.81 Million | +81.70% |
| 1999-09-30 | $7.60 Million | -47.22% |
| 1998-09-30 | $14.40 Million | +128.57% |
| 1997-09-30 | $6.30 Million | -47.06% |
| 1996-09-30 | $11.90 Million | +85.94% |
| 1995-09-30 | $6.40 Million | -20.99% |
| 1994-09-30 | $8.10 Million | -30.17% |
| 1993-09-30 | $11.60 Million | -15.94% |
| 1992-09-30 | $13.80 Million | +762.50% |
| 1991-09-30 | $1.60 Million | +220.00% |
| 1990-09-30 | $500.00K | 0.00% |
| 1989-09-30 | $500.00K | -16.67% |
| 1988-09-30 | $600.00K | -14.29% |
| 1987-09-30 | $700.00K | +133.33% |
| 1986-09-30 | $300.00K | -- |
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more